Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
Roncolato F, King MT, O'Connell RL, Lee YC, Joly F, Hilpert F, Lanceley A, Yoshida Y, Bryce J, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Ledermann JA, Berton D, Sehouli J, Kaminsky MC, Stockler MR, Friedlander M. Roncolato F, et al. Gynecol Oncol. 2024 Feb 26;185:128-137. doi: 10.1016/j.ygyno.2024.02.025. Online ahead of print. Gynecol Oncol. 2024. PMID: 38412736 Free article.
The Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry.
Fox LC, McQuilten ZK, Firkin F, Fox V, Badoux X, Bajel A, Barbaro P, Cole-Sinclair MF, Forsyth C, Gibson J, Hiwase DK, Johnston A, Mills A, Roncolato F, Sutherland R, Szer J, Ting SB, Vilcassim S, Young L, Waters NA, Wood EM; Australian Aplastic Anaemia and other Bone Marrow Failure Syndromes Registry (AAR) Investigators. Fox LC, et al. Among authors: roncolato f. Best Pract Res Clin Haematol. 2023 Dec;36(4):101516. doi: 10.1016/j.beha.2023.101516. Epub 2023 Oct 23. Best Pract Res Clin Haematol. 2023. PMID: 38092475 Free article. Review.
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.
Song Y, Malpica L, Cai Q, Zhao W, Zhou K, Wu J, Zhang H, Mehta-Shah N, Ding K, Liu Y, Li Z, Zhang L, Zheng M, Jin J, Yang H, Shuang Y, Yoon DH, Gao S, Li W, Zhai Z, Zou L, Xi Y, Koh Y, Li F, Prince M, Zhou H, Lin L, Liu H, Allen P, Roncolato F, Yang Z, Kim WS, Zhu J. Song Y, et al. Among authors: roncolato f. Lancet Oncol. 2024 Jan;25(1):117-125. doi: 10.1016/S1470-2045(23)00589-2. Epub 2023 Dec 9. Lancet Oncol. 2024. PMID: 38092009 Clinical Trial.
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma.
Conduit C, Davis ID, Goh JC, Kichenadasse G, Gurney H, Harris CA, Pook D, Krieger L, Parnis F, Underhill C, Adams D, Roncolato F, Joshua A, Ferguson T, Prithviraj P, Morris M, Harrison M, Begbie S, Hovey E, George M, Liow EC, Link EK, McJannett M, Gedye C; Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP); UNISoN Investigators. Conduit C, et al. Among authors: roncolato f. BJU Int. 2024 Feb;133 Suppl 3:57-67. doi: 10.1111/bju.16190. Epub 2023 Nov 20. BJU Int. 2024. PMID: 37986556 Clinical Trial.
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Del Rosario PM, Liu X, Van Nieuwenhuysen E; DUO-E Investigators. Westin SN, et al. J Clin Oncol. 2024 Jan 20;42(3):283-299. doi: 10.1200/JCO.23.02132. Epub 2023 Oct 21. J Clin Oncol. 2024. PMID: 37864337 Free PMC article. Clinical Trial.
A Population-Based Family Case-Control Study of Sun Exposure and Follicular Lymphoma Risk.
Odutola MK, van Leeuwen MT, Bruinsma F, Turner J, Hertzberg M, Seymour JF, Prince HM, Trotman J, Verner E, Roncolato F, Opat S, Lindeman R, Tiley C, Milliken ST, Underhill CR, Benke G, Giles GG, Vajdic CM. Odutola MK, et al. Among authors: roncolato f. Cancer Epidemiol Biomarkers Prev. 2024 Jan 9;33(1):106-116. doi: 10.1158/1055-9965.EPI-23-0578. Cancer Epidemiol Biomarkers Prev. 2024. PMID: 37831120 Free PMC article.
Occupational exposure to extremely low-frequency magnetic fields and follicular lymphoma risk: a family case-control study.
Odutola MK, van Leeuwen MT, Bruinsma FJ, Benke G, Turner MC, Trotman J, Turner J, Seymour JF, Prince HM, Milliken ST, Tiley C, Hertzberg M, Roncolato F, Opat S, Lindeman R, Verner E, Underhill CR, Cardis E, Giles G, Vajdic CM. Odutola MK, et al. Among authors: roncolato f. Occup Environ Med. 2023 Oct;80(10):599-602. doi: 10.1136/oemed-2023-108949. Epub 2023 Sep 18. Occup Environ Med. 2023. PMID: 37722828 Free PMC article.
Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice.
Campbell R, King MT, Stockler MR, Lee YC, Roncolato FT, Friedlander ML. Campbell R, et al. Among authors: roncolato ft. Patient Relat Outcome Meas. 2023 May 8;14:111-126. doi: 10.2147/PROM.S297301. eCollection 2023. Patient Relat Outcome Meas. 2023. PMID: 37188148 Free PMC article. Review.
Dietary intake of animal-based products and likelihood of follicular lymphoma and survival: A population-based family case-control study.
Odutola MK, van Leeuwen MT, Bassett JK, Bruinsma F, Turner J, Seymour JF, Prince HM, Milliken ST, Hertzberg M, Roncolato F, Opat SS, Lindeman R, Tiley C, Trotman J, Verner E, Harvey M, Underhill CR, Benke G, Giles GG, Vajdic CM. Odutola MK, et al. Among authors: roncolato f. Front Nutr. 2023 Jan 4;9:1048301. doi: 10.3389/fnut.2022.1048301. eCollection 2022. Front Nutr. 2023. PMID: 36687712 Free PMC article.
36 results